Zafgen, Inc. (NASDAQ:ZFGN) Files An 8-K Costs Associated with Exit or Disposal Activities
ZAFGEN, INC. Exhibit
EX-10.1 2 d798377dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO SEVERANCE AND CHANGE IN CONTROL AGREEMENT This First Amendment to Severance and Change in Control Agreement (this “Amendment”) is entered into and effective as of September 12,…
To view the full exhibit click here
About Zafgen, Inc. (NASDAQ:ZFGN)
Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.
